[go: up one dir, main page]

MX2018006531A - Agentes para el tratamiento de enfermedades asociadas con la proliferacion celular no deseada. - Google Patents

Agentes para el tratamiento de enfermedades asociadas con la proliferacion celular no deseada.

Info

Publication number
MX2018006531A
MX2018006531A MX2018006531A MX2018006531A MX2018006531A MX 2018006531 A MX2018006531 A MX 2018006531A MX 2018006531 A MX2018006531 A MX 2018006531A MX 2018006531 A MX2018006531 A MX 2018006531A MX 2018006531 A MX2018006531 A MX 2018006531A
Authority
MX
Mexico
Prior art keywords
treatment
agents
cell proliferation
diseases associated
ovarian
Prior art date
Application number
MX2018006531A
Other languages
English (en)
Inventor
SEOANE SUÁREZ Joan
Soto Simon Atenea
Sala Hojman Ada
Huber Ruano Isabel
CHIGANCAS Vanesa
Anido Folgueira Judit
Original Assignee
Fundacio Privada Inst D´Investigacio Oncologica De Vall Hebron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Privada Inst D´Investigacio Oncologica De Vall Hebron filed Critical Fundacio Privada Inst D´Investigacio Oncologica De Vall Hebron
Publication of MX2018006531A publication Critical patent/MX2018006531A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a métodos para el tratamiento del cáncer de ovario, pulmón o colorrectal, mediante el uso de agentes capaces de inhibir la expresión o capaces de bloquear la actividad del factor inhibidor de la leucemia (LIF). La invención también se refiere a métodos in vitro para diseñar una terapia personalizada para un paciente que padece un cáncer de ovario, pulmón o colorrectal y para seleccionar a un paciente que padece alguna de dichas enfermedades, para ser tratado con un agente capaz de inhibir la expresión o capaz de bloquear la actividad del LIF.
MX2018006531A 2015-11-27 2016-11-28 Agentes para el tratamiento de enfermedades asociadas con la proliferacion celular no deseada. MX2018006531A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382590.6A EP3173483A1 (en) 2015-11-27 2015-11-27 Agents for the treatment of diseases associated with undesired cell proliferation
PCT/EP2016/079031 WO2017089614A1 (en) 2015-11-27 2016-11-28 Agents for the treatment of diseases associated with undesired cell proliferation

Publications (1)

Publication Number Publication Date
MX2018006531A true MX2018006531A (es) 2019-01-10

Family

ID=54849575

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018006531A MX2018006531A (es) 2015-11-27 2016-11-28 Agentes para el tratamiento de enfermedades asociadas con la proliferacion celular no deseada.

Country Status (9)

Country Link
US (2) US20180344759A1 (es)
EP (2) EP3173483A1 (es)
JP (2) JP7069013B2 (es)
KR (1) KR20180100316A (es)
AU (2) AU2016359920B2 (es)
CA (1) CA3006168A1 (es)
IL (2) IL305473A (es)
MX (1) MX2018006531A (es)
WO (1) WO2017089614A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3555132T1 (sl) * 2016-12-19 2024-04-30 Medimmune Limited Protitelesa proti LIF in njihove uporabe
WO2018115960A1 (en) * 2016-12-19 2018-06-28 Mosaic Biomedicals, S.L. Antibodies against lif and uses thereof
KR20210021287A (ko) * 2018-04-12 2021-02-25 메디뮨 리미티드 암을 치료하는 데 사용하기 위한 lif 억제제와 pd-1 축 억제제의 조합
KR20210008514A (ko) * 2018-05-14 2021-01-22 메디뮨 리미티드 Lif에 대한 항체 및 이의 투여 형태
WO2019243898A2 (en) * 2018-06-18 2019-12-26 Mosaic Biomedicals Slu Methods for improving response to anti-lif antibody treatment in individuals with cancer
KR20210112346A (ko) * 2019-01-04 2021-09-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 눈에서 혈관신생을 촉진하기 위한 조성물 및 방법
WO2021057991A1 (zh) * 2019-09-29 2021-04-01 北京加科思新药研发有限公司 对lif具有特异性的结合分子及其用途
WO2021110873A1 (en) * 2019-12-04 2021-06-10 Medimmune Limited Antibodies against lif and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
WO1993023556A1 (en) 1992-05-08 1993-11-25 Genentech, Inc. Antibodies to leukemia inhibitory factor
GB9413316D0 (en) 1994-07-01 1994-08-24 Cancer Res Campaign Tech Novel proteins
US6110462A (en) 1999-03-03 2000-08-29 The Scripps Research Institute Enzymatic DNA molecules that contain modified nucleotides
WO2005030803A1 (en) 2003-09-29 2005-04-07 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
ES2363358B1 (es) 2009-04-03 2012-06-21 FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
EP3049110A2 (en) * 2013-09-23 2016-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for targeting tumor microenvironment and for preventing metastasis
TWI486172B (zh) * 2013-11-08 2015-06-01 Univ Chang Gung 鼻咽癌治療的醫藥
CN106687134A (zh) * 2014-09-10 2017-05-17 加利福尼亚大学董事会 通过抗hLIF抗体靶向K‑RAS介导的信号转导通路和恶性肿瘤

Also Published As

Publication number Publication date
EP3173483A1 (en) 2017-05-31
JP7069013B2 (ja) 2022-05-17
IL305473A (en) 2023-10-01
US20180344759A1 (en) 2018-12-06
IL259486B2 (en) 2024-02-01
CA3006168A1 (en) 2017-06-01
AU2016359920B2 (en) 2023-03-02
JP2019502664A (ja) 2019-01-31
WO2017089614A1 (en) 2017-06-01
AU2016359920A1 (en) 2018-06-28
AU2023203443A1 (en) 2023-06-29
JP2022115958A (ja) 2022-08-09
IL259486B1 (en) 2023-10-01
IL259486A (en) 2018-07-31
US20220323478A1 (en) 2022-10-13
KR20180100316A (ko) 2018-09-10
EP3380614A1 (en) 2018-10-03
JP7410211B2 (ja) 2024-01-09

Similar Documents

Publication Publication Date Title
MX2018006531A (es) Agentes para el tratamiento de enfermedades asociadas con la proliferacion celular no deseada.
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
PH12017501857B1 (en) Pd-l1 antagonist combination treatments
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
MX375221B (es) Composiciones que comprenden anticuerpos anti-molécula de adhesión celular relacionada con antígeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cáncer.
MX2022008868A (es) Tratamiento del cancer con tg02.
MX2020011772A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
NZ631701A (en) Apoptosis-including agents for the treatment of cancer and immune and autoimmune diseases
MX363689B (es) Derivados de heterociclicos.
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
NZ631082A (en) Methods for treating cancer using tor kinase inhibitor combination therapy
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
PH12017501879A1 (en) Methods for treating cancer
MX2018015172A (es) Metodos para tratar cancer pancreatico.
PH12019500758A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
ZA201904533B (en) Antibodies against lif and uses thereof
PH12021550035A1 (en) Combination therapy
MX2020013103A (es) Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia.
MX2017016346A (es) Metodos de tratamiento con taselisib.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.